Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Nanosphere test offers new option for CRE superbug detection
February 2016
SHARING OPTIONS:

NORTHBROOK, Ill.—Nanosphere Inc. introduces the Verigene Gram-Negative Blood Culture Test (BC-GN) as the only FDA-cleared test for rapidly identifying the antibiotic resistance gene associated with a new superbug, a type of carbapenem-resistant Enterobacteriaceae (CRE). CREs are resistant to a range of common antibiotics, including penicillin and amoxicillin, and according to the Centers for Disease Control and Prevention, mortality rates associated with these types of infections can be as high as 50 percent. Verigene BC-GN can detect five of the most common causes of CRE, including OXA-48-like carbapenemases, days faster than traditional testing methods.
 
“The increasing number of cases of CRE and the rise of ‘the phantom menace’ superbug underscores the critical need for rapid detection of a broad range of multi-drug resistance genes,” said Michael McGarrity, Nanosphere’s president and CEO. “Our unique ability to identify genetic resistance positions Nanosphere to meet the needs of healthcare providers as they continue to fight the spread of antimicrobial resistance.”
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.